Novartis Loses Bid To End Wyeth ReFacto Patent Suit
Novartis AG has failed to have claims against it dismissed or transferred in an ongoing battle with Wyeth subsidiary Genetics Institute over who legally owns the formula for ReFacto, a drug...To view the full article, register now.
Already a subscriber? Click here to view full article